Helping you find insights on psychedelics as medicine

Papers | Companies | Reports | Events

Leverage our research to stay up-to-date with the
psychedelic transition from trials to practice

Human brain effects of DMT assessed via EEG-fMRI
This neuroimaging study (n=20) aimed to understand the effects of DMT (20mg) on the human brain. The researchers used EEG-fMRI (electroencephalography-functional MRI) to measure brain activity before, during, and after administering DMT to healthy volunteers. They found that DMT increased global functional connectivity (GFC), network disintegration and desegregation, and a compression of the principal cortical gradient.
Category: Papers
Published: 2023-03-23
Psilocybin-assisted therapy for major depressive disorder: An exploratory placebo-controlled, fixed-order trial
This single-blind, placebo-controlled study (n=19) of psilocybin (21mg/70kg) in combination with therapy (ACT, 8x) finds an improvement in depression scores. However, the difference between the psilocybin and placebo groups didn't reach significance. Though the study tried to control for expectancy (placebo) effects, participants (80%) correctly guessed if they received psilocybin.
Category: Papers
Published: 2023-03-23
The unique neural signature of your trip: Functional connectome fingerprints of subjective psilocybin experience
This re-analysis (n=48) of a double-blind study on the effects of psilocybin (12mg, n=21) finds that function connectomes (FCs) become more idiosyncratic, especially in the default-mode network (DMN). Looking specifically at the DMN, the researchers find reduced within-DMN activity and more connectivity with attentional systems.
Category: Papers
Published: 2023-03-23
Mindfulness and Psychedelics
This double-blind, placebo-controlled trial (n=40) aims to investigate the potential neurophysiological synergy effects between mindfulness meditation and psychedelics, particularly Ayahuasca, on experienced meditators.
Category: Trials
Published: 2023-03-23
Psychedelics, Intimacy and Sex Summit
The Psychedelics, Intimacy and Sex Summit is an upcoming virtual event that will take place on April 8th. The summit aims to explore the relationship between psychedelics, intimacy, and sex, and how these topics can be used to cultivate deeper and more meaningful relationships.
Published: 2023-03-20
ALPS Conference 2023
The Awareness Lectures on Psychedelic Science (ALPS) returns for the third edition on 27-29 October 2023 at the Bern Expo (Switzerland). ALPS is a series of lectures and discussions focusing on the scientific research, therapeutic potential, and cultural impact of psychedelic substances.
Published: 2023-03-20
Psychedelic Research Recap February 2023
February presented another productive month for psychedelic research. This recap of the 21 most exciting articles covers intracellular neuroplasticity, brain measures, outcomes from psychedelic-assisted therapy (PAT), psychedelics for new indications, and well-being measures.
Category: Overviews
Published: 2023-03-20
Ibogaine – A legacy within the current renaissance of psychedelic therapy
This review (2023) gives an overview of research into ibogaine. It details animal studies and the human use of ibogaine in stopping addiction. Studies are few and far between, and clinical trials are only now being started.
Category: Papers
Published: 2023-03-17
Tolerability of MDMA in Schizophrenia (TMS)
This open-label trial (n=20) aims to investigate the tolerability of ± 3,4-methylenedioxymethamphetamine (MDMA) in patients with schizophrenia. Impaired social motivation is a negative symptom of schizophrenia that has no effective treatment, and MDMA has shown promise in increasing social motivation and bonding in healthy individuals and other psychiatric conditions such as PTSD.
Category: Trials
Published: 2023-03-16
Experiences of microdosing psychedelics in an attempt to support wellbeing and mental health
This text-based interview study (n=13) explores the experiences and perceived mental health and well-being changes of microdosing psychedelics. The results identified three superordinate themes: 1) Seeking a solution: Agency and rationale; 2) Microdosers as scientists; 3) Catalysing desirable and beneficial effects.
Category: Papers
Published: 2023-03-16

partners

Explore Blossom’s Resources

Interconnected & Contextualized Databases

Find the right paper, company, person in over 3.000 entries & 100.000 parameters

Explore Databases

Well-Researched Reports

Survey the psychedelic landscape with reports on 18 topics, 14 compounds & 20 countries

Explore Reports

Timely Insights

Stay in the loop with the latest articles on research & implementation

Explore Insights

Are you new to psychedelics as medicine? Start with our overview →

Subscribe to The Bloom newsletter

A weekly email, sent on Tuesdays, packed with the latest
psychedelic research, news & actionable insights

Become a psychedelic insider

  • Weekly psychedelic research newsletter
  • Unlimited access to databases
Make an account

Researcher|Sprout Membership

  • All Free membership benefits, Plus:
  • Full reports on Topics & Compounds
  • Full summary reviews of research papers
  • Early access to new articles
  • Detailed meta-data in databases
Join €15 per month

Cancel anytime

partners

“Blossom is democratising access to psychedelic research by presenting papers from a broad range of disciplines in an accessible weekly write-up.”

Josh Hardman

Founder, Psychedelic Alpha

“The Blossom newsletter is a terrific service to the psychedelic research community: a weekly digest that summarises major new findings in a clear, efficient, and informative way. It is a godsend for busy researchers trying to keep abreast of new developments in an increasingly fast-moving field.”

Chris Letheby

Lecturer in Philosophy, University of Western Australia
Author, Philosophy of Psychedelics

“The work that Floris and the Blossom team have done to document, organise and synthesise the emerging psychedelic research has helped me stay up to date with this fast-changing landscape. The Blossom newsletter and database are indispensable resources for anyone who wants to understand the psychedelic science and medicine landscape.”

Zach Heighney

Founder, The Trip Report